Form 4: Blueprint Medicines CFO Landsittel Receives Stock Options and Restricted Stock Units

Michael Landsittel, CFO of Blueprint Medicines, was granted stock options and restricted stock units on March 1, 2024, according to a recent SEC Form 4 filing.

Summary

• Michael Landsittel, the Chief Financial Officer of Blueprint Medicines Corp, reported changes in beneficial ownership to the SEC on March 6, 2024.
• The earliest transaction date reported was March 1, 2024.
• Landsittel was granted 12,500 restricted stock units and options to purchase 25,000 shares of common stock.
• The exercise price for the stock options is $95.12.
• The stock options vest monthly, starting April 1, 2024, over a period of 48 months.
• Following the reported transactions, Landsittel beneficially owns 61,023 shares of common stock and options to purchase 25,000 shares.
• A Limited Power of Attorney was executed on January 31, 2023, granting Tracey McCain, Melissa Masse, Ariel Hurley, and Michael Landsittel the authority to act on behalf of Michael Landsittel for Section 13 and 16 filings.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests.

Positives

• The grant of stock options and restricted stock units aligns the CFO's interests with those of the shareholders.
• The vesting schedule of the stock options encourages long-term commitment from the CFO.

Industry Context

Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, aligning management incentives with shareholder value creation.

Comparison to Industry Standards

• Executive compensation packages, including stock options and restricted stock units, are standard practice among publicly traded biotechnology companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals.
• The vesting schedules and exercise prices are typically structured to incentivize long-term performance and retention, similar to what is observed in this case with Blueprint Medicines.

Stakeholder Impact

• The grant of stock options and restricted stock units can positively impact shareholders by aligning management's interests with the company's long-term success.
• Employees may view the executive compensation package as a sign of the company's commitment to its leadership.

Key Dates